Combining an existing small-molecule protein therapy called tumor necrosis factor related apoptosis-inducing ligand (TRAIL) ...

PSA doubling time is an essential criterion for high-risk biochemically recurrent prostate cancer that should prompt treatment escalation.

OPTYX study shows many patients with advanced prostate cancer preferred oral relugolix over injectables for androgen deprivation therapy.

Dec. 3, 2024 — A special protein can play a key role in the fight against certain types of prostate cancer. Until now, treatments have involved blocking the protein in question that builds a so ...

Among those with intermediate-risk prostate cancer, high PSA levels prior to HIFU led to an increased risk of overall recurrence and treatment failure. Patients with HRR-deficient metastatic ...

Clarity Pharmaceuticals (ASX: CU6) ('Clarity' or 'Company'), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for ...

Combining an existing small-molecule protein therapy called tumor necrosis factor related apoptosis-inducing ligand ...

Jointly Bayer and Orion Corporation-developed NUBEQA (Darolutamide) + Androgen Deprivation Therapy (ADT) in combination with docetaxel is to be the first prostate cancer treatment to be made ...

Salvage Radical Prostatectomy for Recurrent Prostate Cancer Following First-line Nonsurgical Treatment: Validation of the European Association of Urology Criteria in a Large, Multicenter, Contemporary ...

Options include: Until recently, biochemical recurrence was one of the last disease states without compelling data supporting the use of androgen deprivation therapy (ADT) in combination ... grade ...

Combining an existing small-molecule protein therapy called tumor necrosis factor related apoptosis-inducing ligand with ...